ロード中...
Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy
Respiratory syncytial virus (RSV) can cause devastating lower respiratory tract infections in preterm infants or when other serious health problems are present. Immunoprophylaxis with palivizumab (Synagis), a humanized IgG(1) mAb, is the current standard of care for preventing RSV infection in at-ri...
保存先:
| 主要な著者: | , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
National Academy of Sciences
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4000855/ https://ncbi.nlm.nih.gov/pubmed/24711420 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1402458111 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|